참고문헌
- Alvaro D (2009). Serum and bile markers for cholangiocarcinoma. Curr Opin Gastroenterol, 25, 279-84 https://doi.org/10.1097/MOG.0b013e328325a894
- Anderson CD, Pinson CW, Berlin J, Chari RS (2004). Diagnosis and treatment of cholangiocarcinoma. Oncologist, 9, 43-57
- Aneknan P, Kukongviriyapan V, Prawan A, et al (2014). Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. Asian Pac J Cancer Prev, 15, 5071-6 https://doi.org/10.7314/APJCP.2014.15.12.5071
- Barr Fritcher EG, Voss JS, Jenkins SM, et al (2013). Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol, 121, 708-17 https://doi.org/10.1002/cncy.21331
- Blechacz B, Komuta M, Roskams T, Gores GJ (2011). Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol, 8, 512-22 https://doi.org/10.1038/nrgastro.2011.131
- Boonyanugomol W, Chomvarin C, Hahnvajanawong C, Sripa B, Kaparakis-Liaskos M, Ferrero RL (2013). Helicobacter pylori cag pathogenicity island (cagPAI) involved in bacterial internalization and IL-8 induced responses via NOD1- and MyD88-dependent mechanisms in human biliary epithelial cells. PLoS One, 8, 77358 https://doi.org/10.1371/journal.pone.0077358
- Boonyanugomol W, Chomvarin C, Sripa B, et al (2012). Helicobacter pylori in Thai patients with cholangiocarcinoma and its association with biliary inflammation and proliferation. HPB (Oxford), 14, 177-84 https://doi.org/10.1111/j.1477-2574.2011.00423.x
- Braconi C, Huang N, Patel T (2010). MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatol, 51, 881-90
- Burak K, Angulo P, Pasha TM, et al (2004). Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol, 99, 523-6 https://doi.org/10.1111/j.1572-0241.2004.04067.x
- Chan-On W, Kuwahara K, Kobayashi N, et al (2009). Cholangiocarcinomas associated with long-term inflammation express the activation-induced cytidine deaminase and germinal center-associated nuclear protein involved in immunoglobulin V-region diversification. Int J Oncol, 35, 287-95
- Fabbri M, Garzon R, Cimmino A, et al (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA, 104, 15805-10 https://doi.org/10.1073/pnas.0707628104
- Han Y, Zhang W, Liu Y (2013). Identification of hepatomaderived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma. World J Surg, 37, 2419-27 https://doi.org/10.1007/s00268-013-2132-4
- Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxidedependent mechanism. Cancer Res, 60, 184-90
- Johnson C, Han YY, Nathan H, et al (2012). Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer, 1, 58-70
-
Karin M. (2006). Nuclear factor-
${\kappa}B$ in cancer development and progression. Nature, 441, 431-6 https://doi.org/10.1038/nature04870 - Kawanishi S, Hiraku Y, Pinlaor S, Ma N (2006). Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem, 387, 365-72
- Khan SA, Emadossadaty S, Ladep NG, et al (2012). Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol, 56, 848-54. https://doi.org/10.1016/j.jhep.2011.11.015
- Komori J, Marusawa H, Machimoto T, et al (2008). Activationinduced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatol, 47, 888-96 https://doi.org/10.1002/hep.22125
- Koonrungsesomboon N, Na-Bangchang K, Karbwang J (2014). Therapeutic potential and pharmacological activities of Atractylodes lancea (Thunb.) DC. Asian Pac J Trop Med, 7, 421-8 https://doi.org/10.1016/S1995-7645(14)60069-9
- Laothong U, Pinlaor P, Boonsiri P, et al (2013). Melatonin inhibits cholangiocarcinoma and reduces liver injury in Opisthorchis viverrini-infected and N-nitrosodimethylamine-treated hamsters. J Pineal Res, 55, 257-66 https://doi.org/10.1111/jpi.12068
-
Lee GR, Jang SH, Kim CJ, et al (2014). Capsaicin suppresses the migration of cholangiocarcinoma cells by down-regulating matrix metalloproteinase-9 expression via the AMPK-NF-
${\kappa}B$ signaling pathway. Clin Exp Metastasis, 31, 897-907 https://doi.org/10.1007/s10585-014-9678-x - Ling S, Feng T, Ke Q, Fan N, et al (2014). Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep, 31, 2611-8 https://doi.org/10.3892/or.2014.3151
- Mahavorasirikul W, Viyanant V, Chaijaroenkul W, Itharat A, Na-Bangchang K (2010). Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. BMC Complement Altern Med, 10, 55 https://doi.org/10.1186/1472-6882-10-55
- Marrero J (2014). Biomarkers in cholangiocarcinoma. Clin Liver Dis, 3, ??
- Matsumoto K, Onoyama T, Kawata S, et al (2014). Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. Intern Med, 53, 651-4 https://doi.org/10.2169/internalmedicine.53.1410
- Matsumoto Y, Marusawa H, Kinoshita K, et al (2007). Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med, 13, 470-6 https://doi.org/10.1038/nm1566
- Nair SS, Bommana A, Bethony JM, et al (2011). The metastasisassociated protein-1 gene encodes a host permissive factor for schistosomiasis, a leading global cause of inflammation and cancer. Hepatol, 54, 285-95 https://doi.org/10.1002/hep.24354
- Navaneethan U, Njei B, Venkatesh PG, Vargo JJ, Parsi MA (2013). Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc, 79, 943-50
- Oh SW, Yoon YS, Shin SA (2005). Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea national health insurance corporation study. Clin Oncol, 23, 4742-54 https://doi.org/10.1200/JCO.2005.11.726
- Parkin DM (2006). The global health burden of infectionassociated cancers in the year 2002. Int J Cancer, 118, 3030-44 https://doi.org/10.1002/ijc.21731
- Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V (1993). Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev, 2, 537-44.
- Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000). The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol, 95, 204-7 https://doi.org/10.1111/j.1572-0241.2000.01685.x
- Plengsuriyakarn T, Viyanant V, Eursitthichai V, et al (2012a). Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement Altern Med, 12, 12-23 https://doi.org/10.1186/1472-6882-12-12
- Plengsuriyakarn T, Viyanant V, Eursitthichai V, et al (2012b). Cytotoxicity, toxicity, and anticancer activity of Zingiber officinale Roscoe against cholangiocarcinoma. Asian Pac J Cancer Prev, 13, 4597-606 https://doi.org/10.7314/APJCP.2012.13.9.4597
- Prayong P, Mairiang E, Pairojkul C, et al (2014). An interleukin-6 receptor polymorphism is associated with opisthorchiasislinked cholangiocarcinoma risk in Thailand. Asian Pac J Cancer Prev, 15, 5443-7 https://doi.org/10.7314/APJCP.2014.15.13.5443
- Qu Z, Cui N, Qin M, Wu X (2012). Epidemiological survey of biomarkers of hepatitis virus in patients with extrahepatic cholangiocarcinomas. Asia Pac J Clin Oncol, 8, 83-7 https://doi.org/10.1111/j.1743-7563.2011.01466.x
- Razumilava N, Gores GJ (2013). Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol, 11, 13-21 https://doi.org/10.1016/j.cgh.2012.09.009
- Ruys AT, Groot Koerkamp B, Wiggers JK, et al (2013). Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol, 21, 487-500
- Shaib Y, El-Serag HB (2004). The epidemiology of cholangiocarcinoma. Semin Liver Dis, 24, 115-25 https://doi.org/10.1055/s-2004-828889
- Shen J, Wang W, Wu J, et al (2012). Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS One, 7, 47476 https://doi.org/10.1371/journal.pone.0047476
-
Srikoon P, Kariya R, Kudo E, et al (2013). Diethyldithiocarbamate Suppresses an NF-
${\kappa}B$ dependent metastatic pathway in cholangiocarcinoma cells. Asian Pac J Cancer Prev, 14, 4441-6 https://doi.org/10.7314/APJCP.2013.14.7.4441 - Sripa B, Mairiang E, Thinkhamrop B, et al (2009). Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatol, 50, 1273-81
- Sripa B, Pairojkul C (2008). Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol, 24, 349-56 https://doi.org/10.1097/MOG.0b013e3282fbf9b3
- Sriwanitchrak P, Viyanant V, Chaijaroenkul W, et al (2011). Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma. Asian Pac J Cancer Prev, 12, 1503-10
- Stroescu C, Herlea V, Dragnea A, Popescu I (2006). The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointest Liver Dis, 15, 9-14
- Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T (2014). Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Jpn J Clin Oncol, 44, 570-8 https://doi.org/10.1093/jjco/hyu045
- Takeuchi O, Akira S (2010). Pattern recognition receptors and inflammation. Cell, 140, 805-20 https://doi.org/10.1016/j.cell.2010.01.022
- Tao LY, Cai L, He XD, Liu W, Qu Q (2010). Comparison of serum tumor markers for inirahepaiic cholangiocarcinoma and hepatocellular carcinoma. Am Surg, 76, 1210-3
- Thanan R, Pairojkul C, Pinlaor S, et al (2013). Inflammationrelated DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Free Rad Biol Med, 65, 1464-72 https://doi.org/10.1016/j.freeradbiomed.2013.07.034
- Tyson GL, El-Serag HB (2011). Risk factors for cholangiocarcinoma. Hepatology, 54, 173-84
- Ustundag Y, Bayraktar Y (2008). Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol, 14, 6458-66 https://doi.org/10.3748/wjg.14.6458
- Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T (2006). Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res, 66, 10517-24 https://doi.org/10.1158/0008-5472.CAN-06-2130
- Wu ZF, Yang N, Li DY, Zhang HB, Yang GS (2013). Characteristics of intrahepatic cholangiocarcinoma in patients with hepatitis B virus infection: clinicopathologic study of resected tumours. J Viral Hepat, 20, 306-10 https://doi.org/10.1111/jvh.12005
- Xiao M, Gao Y, Wang Y (2014). Helicobacter species infection may be associated with cholangiocarcinoma: a metaanalysis. Int J Clin Pract, 68, 262-70 https://doi.org/10.1111/ijcp.12264
- Yao D, Kunam VK, Li X (2014). A review of the clinical diagnosis and therapy of cholangiocarcinoma. J Int Med Res, 42, 3-16 https://doi.org/10.1177/0300060513505488
- Yeh CN, Chiang KC, Juang HH, et al (2013). Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma. PLoS One, 8, 69928 https://doi.org/10.1371/journal.pone.0069928
- Young ND, Nagarajan N, Lin SJ, Korhonen PK et al (2014). The Opisthorchis viverrini genome provides insights into life in the bile duct. Nat Commun, 5, 4378
- Zhou HB, Hu JY, Hu HP (2014). Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World J Gastroenterol, 20, 5721-9 https://doi.org/10.3748/wjg.v20.i19.5721
피인용 문헌
- Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line vol.290, pp.52, 2015, https://doi.org/10.1074/jbc.M115.668277
- HOXD10 acts as a tumor-suppressive factor via inhibition of the RHOC/AKT/MAPK pathway in human cholangiocellular carcinoma vol.34, pp.4, 2015, https://doi.org/10.3892/or.2015.4194